• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
BGNE

BGNE

BeiGene, Ltd.

NASDAQHealthcareBiotechnologyUS

USD184.71

+0.90 (+0.49%)

Company Profile

CEO

John V. Oyler

IPO Date

2016-02-03

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$184.00

Prev. Close

$183.81

Day Low

$183.91

Day High

$187.42

52W Low

$126.97

52W High

$248.16

Market Cap

$20.21B

Volume

0.33M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

64.1%

Avg Negative

8.0%

Avg Neutral

28.0%

News Feed

Tonight! Novartis, Roche, BeiGene, Others Discuss Global Fight Against Cancer In Covid Era

Forbes·8/27/2021·↑ positive

BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Nasopharyngeal Cancer

Business Wire·8/22/2021·↑ positive

BeiGene Announces Acceptance by Swissmedic of Marketing Authorization Application for BRUKINSA® (Zanubrutinib) in Waldenström's Macroglobulinaemia

Business Wire·8/18/2021·↑ positive

BeiGene's Pediatric Tumor Drug Scores Conditional Approval In China

Benzinga·8/17/2021·↑ positive

BeiGene and EUSA Pharma Announce China NMPA Approval of QARZIBA® (Dinutuximab Beta) for Patients With High-Risk Neuroblastoma

Business Wire·8/17/2021·↑ positive

BeiGene's Brukinsa Prolongs Progression-Free Survival Compared To Chemo In Untreated Blood Cancer Patients

Benzinga·7/30/2021·↑ positive

BeiGene Announces Positive Topline Results from Phase 3 SEQUOIA Trial Comparing BRUKINSA® (Zanubrutinib) to Bendamustine Plus Rituximab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia

Business Wire·7/29/2021·↑ positive

Why BeiGene Stock Soared Today

The Motley Fool·7/28/2021·↓ negative

BeiGene's Brukinsa Scores Second Approval In Canada, This Time For Mantle Cell Lymphoma

Benzinga·7/26/2021·↑ positive

BeiGene Announces Approval in Canada of BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Mantle Cell Lymphoma

Business Wire·7/26/2021·↑ positive